The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?

Jordi Remon^*, Lizza E L Hendriks, Martin Reck

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Downloads (Pure)

Original language	English
Article number	JCO2201737
Journal	Journal of Clinical Oncology
DOIs	https://doi.org/10.1200/jco.22.01737
Publication status	E-pub ahead of print - 3 Nov 2022

Access to Document

Full Text
Final published version, 185 KB
Licence: Taverne
Embargo ends: 3/05/23
Request copy

@article{bd93e17807064b1a8c607d0f07e89b5b,

title = "The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?",

author = "Jordi Remon and Hendriks, {Lizza E L} and Martin Reck",

year = "2022",

month = nov,

day = "3",

doi = "10.1200/jco.22.01737",

language = "English",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - The POSEIDON Trial

T2 - Will Secondary End Points Change Our Clinical Practice?

AU - Remon, Jordi

AU - Hendriks, Lizza E L

AU - Reck, Martin

PY - 2022/11/3

Y1 - 2022/11/3

U2 - 10.1200/jco.22.01737

DO - 10.1200/jco.22.01737

M3 - Editorial

C2 - 36331243

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

M1 - JCO2201737

ER -